Viral diseases continue to pose a serious threat to human health and are a major challenge to public health and prosperity across the globe. The extensive efforts of the global molecular virologists are being focused to understand the molecular biology of viruses and the mechanisms by which they cause diseases.   

The mission of CAMB�s Virology Group is to conduct fundamental research on broad range of viruses and viral diseases to mitigate the emerging viral infections and future severe epidemics and pandemics.

Passionate researchers of CAMB�s Virology Group are committed to develop a deeper insight into virus-host interactions, immune response to virus infection, virus pathogenesis, viral epidemiology, gene expression studies, anti-viral therapeutics and development of diagnostic assays for the detection of different viral infections.

The traditional focus of our group has been wide spectrum of viruses but currently our efforts are concentrated principally on hepatitis C virus because of its significant high bioburden all across Pakistan.

Based on the fact, that host genetic diversity is believed to contribute to the spectrum of clinical and therapeutic outcome in HCV infection, we are studying the gene expression of SOCS1 and SOCS3 in patients treated with different combinations of direct-acting anti-viral drugs. The unique feature of this study is breadth of expertise ranging from PCR, SDS-PAGE, western blot, and mammalian expression system (Huh-7, Hela cell lines) to sequencing.

For the first time we have developed in-house diagnostic assays for detection of HCV infection and currently our group are working to develop in-house diagnostic assays for the detection of Dengue virus, Human papillomavirus (HPV) and Herpes simplex virus (HSV)

Moreover, we are studying the pharmacokinetics of interferon-free regimens as well as their response in general population of Pakistan because the recent development of DAA has revolutionized the area of HCV therapeutics. We have recently reported the high relapse rate of        HCV in DAA treated patients that have not been reported previously and now we are trying to track the underlying cause of this treatment failure with DAA.